Universal CARs, universal T cells, and universal CAR T c

Journal of Hematology and Oncology
11, 132
DOI: 10.1186/s13045-018-0677-2

Citation Report

#	Article	IF	Citations
1	Frontline therapies for untreated chronic lymphoid leukemia. Experimental Hematology and Oncology, 2019, 8, 15.	2.0	11
2	Engineering switchable and programmable universal CARs for CAR T therapy. Journal of Hematology and Oncology, 2019, 12, 69.	6.9	65
3	Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. International Journal of Molecular Sciences, 2019, 20, 5010.	1.8	35
4	Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 751-757.	0.2	19
5	CAR-T â€œthe living drugsâ€, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. Journal of Hematology and Oncology, 2019, 12, 113.	6.9	69
6	Recent updates on CAR T clinical trials for multiple myeloma. Molecular Cancer, 2019, 18, 154.	7.9	71
7	Shortening the ex vivo culture of CD19â€specific CAR Tâ€cells retains potent efficacy against acute lymphoblastic leukemia without CAR Tâ€cellâ€related encephalopathy syndrome or severe cytokine release syndrome. American Journal of Hematology, 2019, 94, E322-E325.	2.0	16
8	Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology, 2019, 10, 2250.	2.2	267
9	TCR-like antibodies in cancer immunotherapy. Journal of Hematology and Oncology, 2019, 12, 99.	6.9	39
10	iNK-CD64/16A cells: a promising approach for ADCC?. Expert Opinion on Biological Therapy, 2019, 19, 1229-1232.	1.4	10
12	The making and function of CAR cells. Immunology Letters, 2019, 212, 53-69.	1.1	19
13	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. Stem Cell Reviews and Reports, 2019, 15, 619-636.	1.7	71
14	Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway. Journal of Hematology and Oncology, 2019, 12, 60.	6.9	62
15	Targeting CLL-1 for acute myeloid leukemia therapy. Journal of Hematology and Oncology, 2019, 12, 41.	6.9	56
16	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. International Journal of Molecular Sciences, 2019, 20, 1903.	1.8	15
17	Novel approaches to promote CAR T-cell function in solid tumors. Expert Opinion on Biological Therapy, 2019, 19, 789-799.	1.4	5
18	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomarker Research, 2019, 7, 9.	2.8	19
19	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. Journal of Hematology and Oncology, 2019, 12, 17.	6.9	80

#	Article	IF	Citations
20	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2019, 12, 15.	6.9	38
21	Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies. Cancers, 2019, 11, 191.	1.7	33
22	Chimeric Antigen Receptor T-Cells: The Future is Now. Journal of Clinical Medicine, 2019, 8, 207.	1.0	20
24	Gut microbiome and CAR-T therapy. Experimental Hematology and Oncology, 2019, 8, 31.	2.0	33
25	CAR T Cell Therapy for Hematological Malignancies. Current Medical Science, 2019, 39, 874-882.	0.7	22
26	Current status and hurdles for CAR-T cell immune therapy. Blood Science, 2019, 1, 148-155.	0.4	5
27	Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduction and Targeted Therapy, 2020, 5, 1.	7.1	1,354
28	The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances, 2020, 40, 107502.	6.0	216
29	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomedicine and Pharmacotherapy, 2020, 121, 109625.	2.5	92
30	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. Leukemia, 2020, 34, 21-34.	3.3	117
31	Improving CAR T cell therapy by optimizing critical quality attributes. Seminars in Hematology, 2020, 57, 33-38.	1.8	22
32	CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2062.	2.2	45
33	Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences, 2020, 21, 5009.	1.8	63
34	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. Frontiers of Medicine, 2020, 14, 711-725.	1.5	8
35	Evaluation of Cytotoxic Potentials of Novel Cyclooxygenase-2 Inhibitor against ALL Lymphocytes and Normal Lymphocytes and Its Anticancer Effect through Mitochondrial Pathway. Cancer Investigation, 2020, 38, 463-475.	0.6	3
36	CAR-T design: Elements and their synergistic function. EBioMedicine, 2020, 58, 102931.	2.7	144
37	CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. , 2020, 8, e000736.		27
38	Beyond CAR T cells: Engineered Vδ9Vγ2 T cells to fight solid tumors. Immunological Reviews, 2020, 298, 117-133.	2.8	9

#	Article	IF	Citations
39	BCMA-targeted immunotherapy for multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 125.	6.9	108
40	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. Journal of Clinical Medicine, 2020, 9, 2967.	1.0	23
41	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Communication and Signaling, 2020, 18, 134.	2.7	28
42	Inhibition of Caspases Improves Non-Viral T Cell Receptor Editing. Cancers, 2020, 12, 2603.	1.7	5
43	Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters. Frontiers in Oncology, 2020, 10, 605380.	1.3	72
44	Gene modification strategies for next-generation CAR T cells against solid cancers. Journal of Hematology and Oncology, 2020, 13, 54.	6.9	98
45	Toward â€œoffâ€theâ€shelfâ€•allogeneic CAR T cells. Advances in Cell and Gene Therapy, 2020, 3, e86.	0.6	20
46	CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon, 2020, 6, e03779.	1.4	19
47	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Frontiers in Immunology, 2020, 11, 1128.	2.2	29
48	Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biology and Therapy, 2020, 21, 570-580.	1.5	23
49	Recent advances in CAR-T cell engineering. Journal of Hematology and Oncology, 2020, 13, 86.	6.9	192
50	PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 2020, 8, 3.	2.8	23
51	Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes. Veterinary Pathology, 2020, 57, 241-252.	0.8	21
52	Taming the T cell. BioTechniques, 2020, 68, 53-55.	0.8	1
53	Engineering precision therapies: lessons and motivations from the clinic. Synthetic Biology, 2021, 6, ysaa024.	1.2	5
54	Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma. Cancers, 2021, 13, 279.	1.7	8
55	Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer. Research in Pharmaceutical Sciences, 2021, 16, 447.	0.6	5
56	Cord blood beyond transplantation: can we use the experience to advance all cell therapies?. British Journal of Haematology, 2021, 194, 14-27.	1.2	6

#	Article	IF	Citations
58	Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Frontiers in Immunology, 2020, 11, 569117.	2.2	26
59	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Frontiers in Immunology, 2020, 11, 608485.	2.2	4
60	Using CRISPR to enhance T cell effector function for therapeutic applications. Cytokine: X, 2021, 3, 100049.	0.5	16
61	Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. Frontiers in Immunology, 2021, 12, 640082.	2.2	64
62	Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review. Translational Cancer Research, 2021, 10, 1559-1567.	0.4	11
63	Chimeric antigen receptor T cell therapy in oncology â€“ Pipeline at a glance: Analysis of the ClinicalTrials.gov database. Critical Reviews in Oncology/Hematology, 2021, 159, 103239.	2.0	21
64	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology (Dordrecht), 2021, 44, 495-523.	2.1	32
65	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. Journal of Hematology and Oncology, 2021, 14, 65.	6.9	50
66	Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery, 2021, 20, 476-488.	21.5	12
67	CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation. Cancers, 2021, 13, 1955.	1.7	4
68	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. Frontiers in Cellular and Infection Microbiology, 2021, 11, 639108.	1.8	13
69	Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. Frontiers in Immunology, 2021, 12, 687822.	2.2	33
70	Key regulators of sensitivity to immunomodulatory drugs in cancer treatment. Biomarker Research, 2021, 9, 43.	2.8	8
71	AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer Journal, 2021, 11, 119.	2.8	46
72	Novel immunotherapies in multiple myeloma â€“ chances and challenges. Haematologica, 2021, 106, 2555-2565.	1.7	21
73	A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Research and Therapy, 2021, 12, 428.	2.4	63
74	Partnership agreements for regenerative medicines: a database analysis and implications for future innovation. Regenerative Medicine, 2021, 16, 733-755.	0.8	0
75	Chimeric antigen receptor T-cell therapy for breast cancer. Future Oncology, 2021, 17, 2961-2979.	1.1	0

#	Article	IF	Citations
76	Application of Immunotherapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 699060.	1.3	8
77	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology, 2022, 237, 346-372.	2.0	13
78	Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. , 2022, 232, 108007.		12
79	Engineering solutions to design CAR-T cells. , 2022, , 1-31.		0
81	Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy. Clinical and Translational Oncology, 2021, 23, 1003-1019.	1.2	26
82	Emerging CAR landscape for cancer immunotherapy. Biochemical Pharmacology, 2020, 178, 114051.	2.0	6
83	Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer. BioMed Research International, 2020, 2020, 1-13.	0.9	42
84	CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 697.	1.3	129
85	The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead. Cancers, 2021, 13, 5174.	1.7	47
86	Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges. Annals of Oncology, 2022, 33, 6-12.	0.6	7
87	Advances in Universal CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 744823.	2.2	78
88	CAR-T cellÂtherapy in T-cell malignancies: Is success a low-hanging fruit?. Stem Cell Research and Therapy, 2021, 12, 527.	2.4	43
89	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. British Journal of Haematology, 2022, 197, 28-40.	1.2	9
90	CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. International Immunopharmacology, 2021, 101, 108260.	1.7	3
91	Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?. Methods in Molecular Biology, 2020, 2115, 407-417.	0.4	1
92	CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes. Cytotherapy, 2022, 24, 101-109.	0.3	9
94	Optimizing sgRNA to Improve CRISPR/Cas9 Knockout Efficiency: Special Focus on Human and Animal Cell. Frontiers in Bioengineering and Biotechnology, 2021, 9, 775309.	2.0	11
95	Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. Translational Oncology, 2022, 16, 101309.	1.7	5

#	Article	IF	Citations
96	Chimeric antigen receptorâ€engineered adoptive cell therapy for AML: Current status and future perspectives. Immunomedicine, 2022, 2, .	0.7	0
97	Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Annals of the New York Academy of Sciences, 2022, 1510, 18-35.	1.8	3
98	Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress. Stem Cell Research and Therapy, 2022, 13, 40.	2.4	28
99	iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting. Frontiers in Immunology, 2022, 13, 841107.	2.2	42
100	Gamma delta (Î³Î´) T cells in cancer immunotherapy; where it comes from, where it will go?. European Journal of Pharmacology, 2022, 919, 174803.	1.7	23
101	In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. Frontiers in Oncology, 2022, 12, 809754.	1.3	24
102	Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. International Immunopharmacology, 2022, 106, 108587.	1.7	15
103	Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer. Antibody Therapeutics, 2022, 5, 73-83.	1.2	5
104	Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy. Cancers, 2022, 14, 967.	1.7	5
105	Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy. Molecular Cancer, 2022, 21, 71.	7.9	15
106	Folate Receptor-Alpha Targeted 7x19 CAR-Î³ÎT Suppressed Triple-Negative Breast Cancer Xenograft Model in Mice. Journal of Oncology, 2022, 2022, 1-9.	0.6	8
107	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. Drug Design, Development and Therapy, 2022, Volume 16, 951-972.	2.0	4
108	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. Drugs, 2022, 82, 491-510.	4.9	18
109	Hurdles to breakthrough in CAR T cell therapy of solid tumors. Stem Cell Research and Therapy, 2022, 13, 140.	2.4	20
110	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
111	Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles. Pharmaceutics, 2021, 13, 2097.	2.0	11
112	Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Science Immunology, 2022, 7, eabl3642.	5.6	22
114	CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cellular and Molecular Biology Letters, 2022, 27, 35.	2.7	12

#	Article	IF	Citations
115	Inadequate reporting quality of registered genome editing trials: an observational study. BMC Medical Research Methodology, 2022, 22, 131.	1.4	1
117	Glioblastoma, an opportunity T cell trafficking could bring for the treatment. Molecular Biology Reports, 0, , .	1.0	4
118	Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity. Cancers, 2022, 14, 2749.	1.7	27
119	Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells. Pharmacology, 2022, 107, 446-463.	0.9	8
120	T Cell Therapies for Cancer. , 2022, 1, 262-270.		0
121	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	33
122	Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud. Cytokine, 2022, 156, 155920.	1.4	4
123	Antibody variable region engineering for improving cancer immunotherapy. Cancer Communications, 2022, 42, 804-827.	3.7	15
124	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. Frontiers in Oncology, 0, 12, .	1.3	4
125	The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. Biomedicines, 2022, 10, 1778.	1.4	10
126	Umbilical cord blood: A promising source for allogeneic CAR-T cells. Frontiers in Oncology, 0, 12, .	1.3	14
127	Current progress in CARâ€T cell therapy for tumor treatment (Review). Oncology Letters, 2022, 24, .	0.8	7
128	A promising antitumor method: Targeting CSC with immune cells modified with CAR. Frontiers in Immunology, 0, 13, .	2.2	6
129	Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3511-3520.	1.2	5
130	The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Biomedicines, 2022, 10, 2286.	1.4	1
131	Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	21
132	Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics. Stem Cell Reviews and Reports, 2023, 19, 309-321.	1.7	2
133	Tumor buster - where will the CAR-T cell therapy â€˜missileâ€™ go?. Molecular Cancer, 2022, 21, .	7.9	23

#	Article	IF	Citations
134	Next generations of CAR-T cells - new therapeutic opportunities in hematology?. Frontiers in Immunology, 0, 13, .	2.2	24
135	Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory. OncoTargets and Therapy, 0, Volume 15, 1229-1243.	1.0	3
136	CAR cell design strategies in solid tumors. International Immunopharmacology, 2022, 113, 109345.	1.7	0
137	Current and Future Perspectives for Chimeric Antigen Receptor T Cells Development in Poland. Biomedicines, 2022, 10, 2912.	1.4	2
138	Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers. , 2023, , 117-155.		1
139	Strategies to enhance CAR-T persistence. Biomarker Research, 2022, 10, .	2.8	15
140	Bottlenecks and opportunities in immunotherapy for glioma: a narrative review. Journal of Bio-X Research, 0, Publish Ahead of Print, .	0.3	0
141	Overcoming current challenges to T-cell receptor therapy via metabolic targeting to increase antitumor efficacy, durability, and tolerability. Frontiers in Immunology, 0, 13, .	2.2	3
142	CAR T-cell therapies in China: rapid evolution and a bright future. Lancet Haematology,the, 2022, 9, e930-e941.	2.2	15
143	RNA Therapeutics for Improving CAR T-cell Safety and Efficacy. Cancer Research, 2023, 83, 354-362.	0.4	6
144	Chimeric antigen receptor T-cell therapy for multiple myeloma. Frontiers in Immunology, 0, 13, .	2.2	4
145	Mechanisms of CAR T cell exhaustion and current counteraction strategies. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	9
146	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology, 2023, 102, 151284.	1.6	8
147	CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines, 2023, 11, 165.	2.1	9
148	Advanced T and Natural Killer Cell Therapy for Glioblastoma. Journal of Korean Neurosurgical Society, 2023, 66, 356-381.	0.5	0
149	Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Experimental Hematology and Oncology, 2023, 12, .	2.0	37
150	Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Frontiers in Immunology, 0, 14, .	2.2	12
151	Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert Opinion on Drug Discovery, 2023, 18, 269-286.	2.5	0

#	Article	IF	Citations
152	â€œOff-the-Shelfâ€•Allogeneic CAR Cell Therapyâ€”Neglected HvG Effect. Current Treatment Options in Oncology, 0, , .	1.3	0
153	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Current Hematologic Malignancy Reports, 2023, 18, 9-18.	1.2	15
154	Induced pluripotent stem cell-derived hematopoietic stem and progenitor cells: potential, challenges, and future perspectives. Organoid, 0, 3, e2.	0.0	0
155	Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine, 2023, 12, 2173.	1.0	6
156	Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell, 2023, 30, 592-610.	5.2	14
157	The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer. Current Issues in Molecular Biology, 2023, 45, 3359-3374.	1.0	0
158	Gene Targets of CAR-T Cell Therapy for Glioblastoma. Cancers, 2023, 15, 2351.	1.7	4
176	Cellular Therapies: A Description of the Types of Existing Cellular Therapies and Associated Toxicities. , 2023, , 55-67.		0
177	CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clinical and Translational Oncology, 0, , .	1.2	0
179	Collection of Hematopoietic Stem Cells and Cell Therapy Products. , 2024, , .		0